The association of hepatitis C infection with the onset of CKD and progression into ESRD
- PMID: 30496620
- PMCID: PMC6410728
- DOI: 10.1111/sdi.12759
The association of hepatitis C infection with the onset of CKD and progression into ESRD
Abstract
Hepatitis C virus (HCV) infection is not only an important cause of chronic liver disease, but extrahepatic manifestations are common and include chronic kidney disease (CKD). HCV is classically associated with cryoglobulinemic glomerulonephritis in the context of mixed cryoglobulinemia syndrome, but other glomerular diseases also occur and may be significantly under-recognized. HCV may cause glomerular disease by immune complex deposition; however, other potential mechanisms by which HCV promotes CKD include a direct cytopathic effect of the virus on renal tissue, and by its association with accelerated atherosclerosis, insulin resistance, and chronic inflammation. Epidemiologic studies show HCV infection confers an increased risk of incident CKD and accelerates progression of CKD to end-stage renal disease (ESRD) in the general population, as well as subpopulations including diabetic patients, those coinfected with human immunodeficiency virus (HIV), and kidney transplant recipients. Patients with CKD and HCV infection experience inferior clinical outcomes, including poorer quality of life and an increased risk of mortality. Treatment with interferon-based regimens is associated with decreased risk of incident CKD and ESRD, though prior studies are limited by the small number of patients with HCV and CKD who underwent treatment. With the advent of new, well-tolerated direct-acting antiviral combinations that are not cleared by the kidneys, it is possible to treat all genotypes of HCV infection in patients with CKD and ESRD. More data on the effect of direct-acting antivirals on CKD incidence and progression are necessary. However, there is every expectation that with improved access to HCV treatment, the burden of CKD in patients with HCV could significantly decline.
© 2018 Wiley Periodicals, Inc.
Conflict of interest statement
Disclosures:
JBH has no conflicts to declare.
Figures
Similar articles
-
[Hepatitis C virus and chronic progressive kidney disease].Acta Med Croatica. 2009 Dec;63(5):431-6. Acta Med Croatica. 2009. PMID: 20198903 Croatian.
-
Hepatitis C virus infection and chronic kidney disease: Time for reappraisal.J Hepatol. 2016 Oct;65(1 Suppl):S82-S94. doi: 10.1016/j.jhep.2016.06.011. J Hepatol. 2016. PMID: 27641990 Review.
-
Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis.Hemodial Int. 2018 Apr;22 Suppl 1:S81-S96. doi: 10.1111/hdi.12649. Hemodial Int. 2018. PMID: 29694729 Review.
-
Treating hepatitis C virus in dialysis patients: How, when, and why?Semin Dial. 2019 Mar;32(2):152-158. doi: 10.1111/sdi.12764. Epub 2018 Nov 26. Semin Dial. 2019. PMID: 30475415 Review.
-
ESRD patients coinfected with human immunodeficiency virus and Hepatitis C: Outcomes and management challenges.Semin Dial. 2019 Mar;32(2):159-168. doi: 10.1111/sdi.12765. Epub 2018 Nov 26. Semin Dial. 2019. PMID: 30475425 Free PMC article. Review.
Cited by
-
HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study.BMC Infect Dis. 2019 Aug 23;19(1):712. doi: 10.1186/s12879-019-4315-6. BMC Infect Dis. 2019. PMID: 31438873 Free PMC article.
-
Effects of comprehensive nursing interventions on wound pain in patients undergoing catheter insertion for peritoneal dialysis.Int Wound J. 2024 Apr;21(4):e14795. doi: 10.1111/iwj.14795. Int Wound J. 2024. Retraction in: Int Wound J. 2025 Apr;22(4):e70448. doi: 10.1111/iwj.70448. PMID: 38572781 Free PMC article. Retracted. Clinical Trial.
-
Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection.World J Hepatol. 2022 Jun 27;14(6):1053-1073. doi: 10.4254/wjh.v14.i6.1053. World J Hepatol. 2022. PMID: 35978668 Free PMC article. Review.
-
Facilitating Patient-Centered Decision Making Around the Timing of Direct-Acting Antivirals in Patients With Hepatitis C Virus and CKD.Kidney Med. 2019 Jul 13;1(4):150-152. doi: 10.1016/j.xkme.2019.07.001. eCollection 2019 Jul-Aug. Kidney Med. 2019. PMID: 32734965 Free PMC article. No abstract available.
-
Exploring the causal role of pathogen-derived antibodies in major urinary and kidney diseases: Insights from generalized summary data-based Mendelian randomization.Virulence. 2025 Dec;16(1):2473631. doi: 10.1080/21505594.2025.2473631. Epub 2025 Mar 11. Virulence. 2025. PMID: 40033947 Free PMC article.
References
-
- Global Hepatitis Report 2017 Geneva: World Health Organization;2017.
-
- Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 2014;46 Suppl 5:S165–173. - PubMed
-
- Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of Hepatitis C: A Meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology 2016;150(7):1599–1608. - PubMed
-
- Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;328(7):465–470. - PubMed
-
- Agnello V, Chung RT, Kaplan LM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992;327(21):1490–1495. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical